The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Fibromyalgia Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened pain response to pressure.
The global Fibromyalgia Drugs market size is expected to reach US$ 3239.1 million by 2029, growing at a CAGR of 1.8% from 2023 to 2029. The market is mainly driven by the significant applications of Fibromyalgia Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Fibromyalgia Drugs market. Serotonin Norepinephrine Reuptake Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the GABA Analogs segment is estimated at % CAGR for the next seven-year period.
The APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Fibromyalgia Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Fibromyalgia Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Fibromyalgia Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Fibromyalgia Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Fibromyalgia Drugs covered in this report include Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika and Switch Biotech, etc.
The global Fibromyalgia Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Global Fibromyalgia Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Fibromyalgia Drugs market, Segment by Type:
Serotonin Norepinephrine Reuptake Inhibitors
GABA Analogs
Other
Global Fibromyalgia Drugs market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Fibromyalgia Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened pain response to pressure.
The global Fibromyalgia Drugs market size is expected to reach US$ 3239.1 million by 2029, growing at a CAGR of 1.8% from 2023 to 2029. The market is mainly driven by the significant applications of Fibromyalgia Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Fibromyalgia Drugs market. Serotonin Norepinephrine Reuptake Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the GABA Analogs segment is estimated at % CAGR for the next seven-year period.
The APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Fibromyalgia Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Fibromyalgia Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Fibromyalgia Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Fibromyalgia Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Fibromyalgia Drugs covered in this report include Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika and Switch Biotech, etc.
The global Fibromyalgia Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Global Fibromyalgia Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Fibromyalgia Drugs market, Segment by Type:
Serotonin Norepinephrine Reuptake Inhibitors
GABA Analogs
Other
Global Fibromyalgia Drugs market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Fibromyalgia Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Fibromyalgia Drugs
1.1 Fibromyalgia Drugs Market Overview
1.1.1 Fibromyalgia Drugs Product Scope
1.1.2 Fibromyalgia Drugs Market Status and Outlook
1.2 Global Fibromyalgia Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Fibromyalgia Drugs Market Size by Region (2018-2029)
1.4 Global Fibromyalgia Drugs Historic Market Size by Region (2018-2023)
1.5 Global Fibromyalgia Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Fibromyalgia Drugs Market Size (2018-2029)
1.6.1 North America Fibromyalgia Drugs Market Size (2018-2029)
1.6.2 Europe Fibromyalgia Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Fibromyalgia Drugs Market Size (2018-2029)
1.6.4 Latin America Fibromyalgia Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Fibromyalgia Drugs Market Size (2018-2029)
2 Fibromyalgia Drugs Market by Type
2.1 Introduction
2.1.1 Serotonin Norepinephrine Reuptake Inhibitors
2.1.2 GABA Analogs
2.1.3 Other
2.2 Global Fibromyalgia Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Fibromyalgia Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Fibromyalgia Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Fibromyalgia Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Fibromyalgia Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Fibromyalgia Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Fibromyalgia Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Fibromyalgia Drugs Revenue Breakdown by Type (2018-2029)
3 Fibromyalgia Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Fibromyalgia Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Fibromyalgia Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Fibromyalgia Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Fibromyalgia Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Fibromyalgia Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Fibromyalgia Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Fibromyalgia Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Fibromyalgia Drugs Revenue Breakdown by Application (2018-2029)
4 Fibromyalgia Drugs Competition Analysis by Players
4.1 Global Fibromyalgia Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Fibromyalgia Drugs as of 2022)
4.3 Date of Key Players Enter into Fibromyalgia Drugs Market
4.4 Global Top Players Fibromyalgia Drugs Headquarters and Area Served
4.5 Key Players Fibromyalgia Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Fibromyalgia Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Fibromyalgia Drugs Products, Services and Solutions
5.1.4 Pfizer Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Fibromyalgia Drugs Products, Services and Solutions
5.2.4 Eli Lilly Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Actavis
5.3.1 Actavis Profile
5.3.2 Actavis Main Business
5.3.3 Actavis Fibromyalgia Drugs Products, Services and Solutions
5.3.4 Actavis Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Merck Sharp and Dohme Recent Developments
5.4 Merck Sharp and Dohme
5.4.1 Merck Sharp and Dohme Profile
5.4.2 Merck Sharp and Dohme Main Business
5.4.3 Merck Sharp and Dohme Fibromyalgia Drugs Products, Services and Solutions
5.4.4 Merck Sharp and Dohme Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Merck Sharp and Dohme Recent Developments
5.5 Daiichi Sankyo
5.5.1 Daiichi Sankyo Profile
5.5.2 Daiichi Sankyo Main Business
5.5.3 Daiichi Sankyo Fibromyalgia Drugs Products, Services and Solutions
5.5.4 Daiichi Sankyo Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Daiichi Sankyo Recent Developments
5.6 Innovative Med Concepts
5.6.1 Innovative Med Concepts Profile
5.6.2 Innovative Med Concepts Main Business
5.6.3 Innovative Med Concepts Fibromyalgia Drugs Products, Services and Solutions
5.6.4 Innovative Med Concepts Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Innovative Med Concepts Recent Developments
5.7 Meda
5.7.1 Meda Profile
5.7.2 Meda Main Business
5.7.3 Meda Fibromyalgia Drugs Products, Services and Solutions
5.7.4 Meda Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Meda Recent Developments
5.8 Meiji Seika
5.8.1 Meiji Seika Profile
5.8.2 Meiji Seika Main Business
5.8.3 Meiji Seika Fibromyalgia Drugs Products, Services and Solutions
5.8.4 Meiji Seika Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Meiji Seika Recent Developments
5.9 Switch Biotech
5.9.1 Switch Biotech Profile
5.9.2 Switch Biotech Main Business
5.9.3 Switch Biotech Fibromyalgia Drugs Products, Services and Solutions
5.9.4 Switch Biotech Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Switch Biotech Recent Developments
5.10 Theravance
5.10.1 Theravance Profile
5.10.2 Theravance Main Business
5.10.3 Theravance Fibromyalgia Drugs Products, Services and Solutions
5.10.4 Theravance Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Theravance Recent Developments
5.11 Zynerba Pharmaceuticals
5.11.1 Zynerba Pharmaceuticals Profile
5.11.2 Zynerba Pharmaceuticals Main Business
5.11.3 Zynerba Pharmaceuticals Fibromyalgia Drugs Products, Services and Solutions
5.11.4 Zynerba Pharmaceuticals Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Zynerba Pharmaceuticals Recent Developments
5.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
5.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Profile
5.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Main Business
5.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Products, Services and Solutions
5.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Developments
6 North America
6.1 North America Fibromyalgia Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Fibromyalgia Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Fibromyalgia Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Fibromyalgia Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Fibromyalgia Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Fibromyalgia Drugs Market Dynamics
11.1 Fibromyalgia Drugs Industry Trends
11.2 Fibromyalgia Drugs Market Drivers
11.3 Fibromyalgia Drugs Market Challenges
11.4 Fibromyalgia Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
